 |
4 Diseases |  |
51 Trials |
|
51 Trials |  |
979 News |  |
| «12...234567891011121314» |
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CA209-906: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (clinicaltrials.gov) - Jan 9, 2019
P1, N=32, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Feb 2022 --> Feb 2025 | Trial primary completion date: Feb 2019 --> Feb 2020
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na (clinicaltrials.gov) - Jan 3, 2019
P2, N=42, Not yet recruiting, Sponsor: John Kirkwood
- | Opdivo (nivolumab) / BMS
Enrollment open, Combination therapy, PD(L)-1 Biomarker, Metastases: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Nov 20, 2018
P2, N=340, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Feb 2022 --> Feb 2025 | Trial primary completion date: Feb 2019 --> Feb 2020 Active, not recruiting --> Recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Biomarker, Enrollment open, Combination therapy, PD(L)-1 Biomarker, Metastases: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (clinicaltrials.gov) - Nov 15, 2018
P2, N=64, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases: CA209-8DP: Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma (clinicaltrials.gov) - Nov 14, 2018
P2, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: May 2026 --> Nov 2026 | Initiation date: May 2018 --> Nov 2018 | Trial primary completion date: May 2023 --> Nov 2023
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Mismatch repair, Metastases: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (clinicaltrials.gov) - Nov 8, 2018
P2, N=21, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting | Trial completion date: May 2026 --> Nov 2026 | Initiation date: May 2018 --> Nov 2018 | Trial primary completion date: May 2023 --> Nov 2023 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Nov 7, 2018
P2, N=340, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Enrollment change, Trial completion date, Checkpoint inhibition, Checkpoint block, Metastases: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Nov 2, 2018
P2, N=53, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Recruiting | N=30 --> 53 | Trial completion date: Feb 2021 --> Feb 2020
- | Breyanzi (lisocabtagene maraleucel) / BMS
Trial completion date, Trial primary completion date: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Oct 30, 2018
P1/2, N=100, Recruiting, Sponsor: Celgene
Active, not recruiting --> Recruiting | N=30 --> 53 | Trial completion date: Feb 2021 --> Feb 2020 Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker, Metastases: Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (clinicaltrials.gov) - Oct 29, 2018
P2, N=36, Not yet recruiting, Sponsor: Elizabeth Davis
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Biomarker, New P2 trial, Combination therapy, PD(L)-1 Biomarker, Metastases: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (clinicaltrials.gov) - Aug 21, 2018
P2, N=64, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 14, 2018
P1, N=45, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022 Trial primary completion date: Sep 2018 --> Jun 2020
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P2 trial, Tumor mutational burden, Metastases: NCI-2018-01517: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma (clinicaltrials.gov) - Aug 8, 2018
P2, N=20, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Aug 1, 2018
P1/2, N=132, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2018 --> Jun 2020 Trial primary completion date: Jun 2018 --> Dec 2018
- | Opdivo (nivolumab) / BMS
New P1/2 trial, Combination therapy, Metastases, Immuno-oncology: REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (clinicaltrials.gov) - Aug 1, 2018
P1/2, N=30, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P2 trial, Mismatch repair, Metastases: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (clinicaltrials.gov) - Jul 31, 2018
P2, N=21, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- ||| Breyanzi (lisocabtagene maraleucel) / BMS
Enrollment change: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Jul 19, 2018
P1/2, N=100, Recruiting, Sponsor: Celgene
Trial primary completion date: Jun 2018 --> Dec 2018 N=50 --> 100
- |||| Enrollment open, Combination therapy, Metastases: RELATIVITY-048: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Jun 6, 2018
P1/2, N=230, Recruiting, Sponsor: Bristol-Myers Squibb
N=50 --> 100 Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) (clinicaltrials.gov) - May 31, 2018
P1, N=100, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting N=68 --> 100 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2018 --> Aug 2019
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: CA209-8DP: Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma (clinicaltrials.gov) - May 11, 2018
P2, N=40, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Metastases: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - May 1, 2018
P1/2, N=1000, Recruiting, Sponsor: Bristol-Myers Squibb
N=68 --> 100 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Aug 2020
- ||| Opdivo (nivolumab) / BMS
Enrollment closed, Combination therapy, PD(L)-1 Biomarker, Metastases: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Apr 30, 2018
P2, N=340, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Aug 2020 Recruiting --> Active, not recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, Checkpoint inhibition, Checkpoint block: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) - Apr 10, 2018
P1, N=15, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Checkpoint inhibition: NICHE: Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (clinicaltrials.gov) - Mar 9, 2018
P2, N=60, Recruiting, Sponsor: The Netherlands Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2019 --> Jun 2019
- ||||| New P1/2 trial, Combination therapy, Metastases: RELATIVITY-048: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Mar 8, 2018
P1/2, N=230, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Biomarker, Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: ADVISE: An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (clinicaltrials.gov) - Feb 15, 2018
P1, N=50, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2019 --> Jun 2019 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2021 --> Jan 2020 | Trial completion date: Mar 2021 --> Jan 2022 | Initiation date: Dec 2017 --> Feb 2018
- relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block, Metastases: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Feb 8, 2018
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2021 --> Jan 2020 | Trial completion date: Mar 2021 --> Jan 2022 | Initiation date: Dec 2017 --> Feb 2018 Trial primary completion date: Feb 2019 --> Feb 2020 | Trial completion date: Feb 2019 --> Feb 2021
- || Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Jan 11, 2018
P2, N=340, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Feb 2019 --> Feb 2020 | Trial completion date: Feb 2019 --> Feb 2021 Trial primary completion date: Mar 2018 --> Jan 2019
- | Biomarker, New P2 trial, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Dec 19, 2017
P2, N=6452, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Breyanzi (lisocabtagene maraleucel) / BMS
Enrollment open: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Nov 27, 2017
P1/2, N=50, Recruiting, Sponsor: Celgene
Trial primary completion date: Mar 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- | Biomarker, New P1 trial, PD(L)-1 Biomarker, IO biomarker: ADVISE: An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (clinicaltrials.gov) - Nov 7, 2017
P1, N=50, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Breyanzi (lisocabtagene maraleucel) / BMS
New P1/2 trial: PLATFORM: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Oct 15, 2017
P1/2, N=50, Not yet recruiting, Sponsor: Celgene
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment change, Combination therapy, Metastases: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Sep 19, 2017
P1/2, N=1000, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=360 --> 1000
- relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment change, Combination therapy, Metastases: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 28, 2017
P1, N=45, Recruiting, Sponsor: Bristol-Myers Squibb
N=360 --> 1000 N=27 --> 45
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Checkpoint inhibition, Checkpoint block, Metastases: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Jul 18, 2017
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=27 --> 45 Recruiting --> Active, not recruiting | N=40 --> 30
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Jul 2, 2017
P1/2, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=40 --> 30 Trial primary completion date: May 2018 --> Jun 2019
- ||| Enrollment change, Combination therapy, Metastases, Immuno-oncology: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jul 2, 2017
P2, N=200, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2018 --> Jun 2019 N=650 --> 200
- relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker: CA209-906: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (clinicaltrials.gov) - Jun 14, 2017
P1, N=32, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=650 --> 200 Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Jun 4, 2017
P1/2, N=500, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> May 2019
- ||| Enrollment change, Combination therapy, Metastases, Immuno-oncology: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Jun 1, 2017
P2, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2018 --> May 2019 N=910 --> 300
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Apr 27, 2017
P1/2, N=132, Recruiting, Sponsor: Bristol-Myers Squibb
N=910 --> 300 Trial primary completion date: Feb 2018 --> Jun 2018
- ||| Opdivo (nivolumab) / BMS
Enrollment change, Trial primary completion date, Combination therapy, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Apr 19, 2017
P2, N=340, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Feb 2018 --> Jun 2018 N=260 --> 340 | Trial primary completion date: Jul 2017 --> Mar 2018
- | Opdivo (nivolumab) / BMS
Phase classification, Combination therapy, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Mar 29, 2017
P1/2, N=500, Recruiting, Sponsor: Bristol-Myers Squibb
N=260 --> 340 | Trial primary completion date: Jul 2017 --> Mar 2018 Phase classification: P2 --> P1/2
- | Biomarker, Enrollment change, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Mar 24, 2017
P2, N=6452, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P1/2 N=3000 --> 6452
- | Opdivo (nivolumab) / BMS
Phase classification, Combination therapy, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Mar 9, 2017
P2, N=500, Recruiting, Sponsor: Bristol-Myers Squibb
N=3000 --> 6452 Phase classification: P1/2 --> P2
- || Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Mar 7, 2017
P2, N=260, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1/2 --> P2 Trial primary completion date: Mar 2017 --> Jul 2017
- relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 20, 2017
P1, N=27, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2017 --> Jul 2017 Trial primary completion date: Jul 2020 --> Sep 2018
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Checkpoint inhibition: NICHE: Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (clinicaltrials.gov) - Feb 18, 2017
P2, N=60, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial primary completion date: Jul 2020 --> Sep 2018 Not yet recruiting --> Recruiting
- |||| Enrollment open, Combination therapy, Metastases, Immuno-oncology: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Feb 8, 2017
P2, N=650, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P1 trial, PD(L)-1 Biomarker, IO biomarker: CA209-906: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (clinicaltrials.gov) - Feb 7, 2017
P1, N=32, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center